## Special Issue

# Advances in Plasma Oncology toward Clinical Translation

## Message from the Guest Editors

In the past decade, cold atmospheric plasmas (CAPs) have been under investigation for their potential for cancer treatment, thus opening field of plasma oncology. CAPs are tunable sources for the production and delivery of reactive oxygen and nitrogen species (RONS), which positions them as a unique tool to study intracellular redox pathways and for development as a novel redox therapy. The role of the tumor microenvironment is attracting greater attention among plasma-cancer researchers. Strategies for combination therapy, e.g., immunotherapy, are also of great importance and are currently under development. In this Special Issue, we will publish original research papers that provide fundamental understanding into the mechanisms of CAPs in cancer treatment, ranging from computer modeling to in vitro and in vivo experiments and clinical trials.

#### **Guest Editors**

Prof. Dr. Annemie Bogaerts

Dr. Katharina Stapelmann

Dr. Abraham Lin

## Deadline for manuscript submissions

closed (1 January 2021)



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/37628

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

